1045 – Acceptability of a Dolutegravir Dispersible Tablet and a Novel Oral Film Formulation in Neonates
Background Current antiretroviral (ARV) syrups used for HIV prevention and early treatment in neonates are from older, more toxic drug classes. Dolutegravir (DTG) is one of the preferred ARVs for children, but there is no pediatric formulation specifically tailored for use in neonates. We report on the mothers’ acceptability of DTG dispersible tablets (DTG-DT) and…